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Introduction
In the last years hepatocellular carcinoma (HCC) recurrence 
after liver transplantation (LT) has attracted great attention 
in the transplant community. Despite a careful selection 
of candidates for LT and optimization of bridging loco-
regional therapies within the waiting list, HCC recurrence 
rate is still up to 15–20%, despite a 5-year survival rate of 
70% after LT (1,2).
In order to improve the outcome of HCC recipients, 
in the last decades different criteria have been proposed 
in order to stage the pre-LT HCC status and its related 
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prognosis after transplantation. These include the Milan 
Criteria and its implementation, the University of California 
San Francisco criteria, the Barcelona-Clinic Liver Cancer 
criteria, the Asan Medical Center criteria, the University 
Clinic of Navarra’s criteria and the Kyoto criteria (3).
HCC recurrence has been associated with several 
“oncological” risk factors, such as compliance to Milan and 
other criteria, tumour size, Edmondson-Steiner histology 
grades, the vascular and capsular invasion and alpha-
fetoprotein blood levels (4,5), as well as several “non-
oncological” risk factors, including immunosuppressive (IS) 
drugs, type of donor (living-donor vs. deceased-donor), graft-
related variables (e.g., ischemia-reperfusion injury), recipient 
characteristics (body mass index, age) and waiting-list time 
to LT (6). The principal mechanisms of HCC recurrence are 
considered related to the sub-clinical extrahepatic spread of 
tumour at time of LT and/or nesting of tumoral cells during 
the manipulation of the liver during surgery.
The current strategies to minimize HCC recurrence 
after LT are mainly based on (I) a careful selection of 
candidates with HCC for LT; (II) the optimization of 
patient management within the waiting list (through 
the prioritization and bridging strategies); (III) the 
administration of a tailored IS regimen in the post-
transplant period.
Nowadays, the identification of the optimal IS regimen in 
HCC recipients is one of the main goals after LT. IS therapy 
is essential in preventing graft rejection, however presenting 
a well-established association with oncogenesis (2). 
The immune system has a key role as a defending mechanism 
against cancer development, preventing vascular invasion 
and/or metastasis and its depression has been largely 
associated with de novo and recurrent malignancies (7). 
Therefore, the relation between tumour recurrence and the 
type of IS therapy is crucial in HCC recipients, representing 
one of the few risk factors modifiable after LT. 
A tailored IS regimen is essential to gain the optimal 
balance between the risk of rejection and the risk of HCC 
recurrence. So far, a complete withdrawal of IS drugs after 
LT has been reported to be safely achievable in 25% of 
patients (defined as “operational tolerant”), without the 
risk of graft loss (8). IS weaning has the benefit of reducing 
IS-related side effects such as infections, diabetes, renal 
failure, cardiovascular diseases and de novo tumours (9-11). 
Therefore, in HCC-LT recipients, IS withdrawal could 
theoretically contribute to reduce the risk of tumour 
recurrence, which represents the major drawback in these 
recipients. 
Herein, we review the current literature on IS weaning 
in recipients who underwent LT for HCC as primary 
indication and we report our experience on IS withdrawal in 
HCC recipients.
Immunosuppression drugs and HCC recurrence
Calcineurin inhibitors (CNIs) are the mostly used IS 
drugs after solid organ transplantation. Its introduction 
has improved patient and graft outcomes; however, CNIs 
have shown to be a risk factor for HCC recurrence. CNIs 
promote the proliferation of malignant cells in a dose-
dependent fashion through the increase of angiogenesis 
and cancer cell invasiveness, activation of pro-oncogenes, 
and enhance tumour growth factor-β (TGF-β) expression, 
inducing resistance to apoptosis and increasing the likelihood 
of metastasis (12). Several retrospective studies reported that 
HCC recurrence is related to CNIs’ dose-exposure: high 
doses of CNIs (mean trough concentrations of tacrolimus 
>10 ng/mL or cyclosporine >300 ng/mL) during the first 
postoperative period exerted a negative impact on HCC 
recipients with higher tumour recurrence rates (12).
In recent years, the introduction of IS regimens based 
on mammalian target of rapamycin inhibitors (mTORi), 
sirolimus and everolimus, provided a new potential tool to 
prevent HCC recurrence after LT. The mTOR pathway, 
in fact, plays a central function in the cellular metabolism, 
growth and proliferation and its up-regulation is present in 
up to 50% of HCC tumours (13). 
Sirolimus was the first developed mTORi and its 
potential anti-tumour effect has been documented by 
several studies, improving the overall patient survival 
rate in HCC recipients (14,15). A recent meta-analysis 
showed that sirolimus-based IS regimens decrease tumour 
recurrence and improve LT outcomes, with no significant 
difference in major post-transplant complications (16). 
In 2014, a systematic review of 3,666 HCC LT patients 
from 42 studies reported that recipients treated with 
CNIs developed HCC recurrence significantly more 
frequently, compared to those receiving mTORi (13.8% 
vs. 8%, P<0.001). Moreover, patients under everolimus had 
significantly lower recurrence rates of HCC, compared with 
those on sirolimus or CNIs (4.1% vs. 10.5% vs. 13.8%, 
respectively, P<0.05) (17).
Despite the above consideration, more recently, the 
results from the SiLVER study definitely showed that LT 
recipients treated with mTORi were not superior in terms of 
recurrence free survival (18).
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Antimetabolite drugs have a controversial role in 
preventing HCC recurrence. Long-term use of azathioprine 
increases the risk of lymphoma and non-melanoma skin 
cancer, but there is no evident effect on HCC (19). So 
far, mycophenolate did not show any effect on HCC 
recurrence, despite it seems to be protective against other 
malignancies after transplantation (20,21).
Recently, other immune-modulator drugs such as 
sorafenib and belacept, has been associated with the 
conventional IS regimens after LT with promising results, 
but further data are needed (22,23).
Moreover, new specific immunotherapies such as 
dendritic cell vaccination and immune checkpoint inhibition 
are under investigation for the treatment of HCC after 
loco-regional treatment and could potentially be used also 
in the post-transplant setting (24).
Operational tolerance after liver transplantation
The status of “tolerance” after a solid organ transplantation 
is defined as a “functioning graft without histological sign of 
rejection in the absence of IS and in an immunocompetent 
host that can accept a second graft from the same donor but 
reject a graft from a different third-party donor” (25). In other 
words, tolerance is the non-reactivity of immune system, 
that has not been suppressed by IS, to one or more antigens. 
In LT, the term of clinical operational tolerance (COT) is 
defined as a “transplant retaining function without features of 
acute or chronic rejection in the absence of any IS” (26).
The mechanisms of spontaneous allograft acceptance in 
LT recipients are not completely clear yet. The liver is less 
likely to be rejected than other solid transplanted organs and 
a number of mechanisms, in order to explain this peculiarity, 
have been proposed: (I) the liver seems to produce high 
levels of soluble major histocompatibility complex (MHC) 
that could impact in recipients’ immune response (27); (II) 
the donor liver appears to present hematopoietic stem cells 
influencing the recipients’ chimerism (28); (III) during LT a 
number of donor liver leukocytes migrate into the recipient 
blood stream and this could contribute to the graft’s tolerance, 
as their depletion by irradiation in the donor led to organ 
rejection (29); (IV) the size of the liver, which is approximately 
10 times greater than other transplantable organs (heart, 
kidney or pancreas), can act as a cytokine sink and/or dilute 
the clones of alloreactive T cells and thus potentially exhaust 
the recipients’ immune response; (V) the liver is a unique 
organ for its microenvironment and microcirculation since 
it is constantly exposed to different antigens deriving from 
intestine bacteria and/or food and this could be responsible 
for a major acceptance of allograft rather than other organs. 
The first series of COT in LT was described by the 
Pittsburgh group in the early 1990s, reporting 11 recipients 
who completely withdrew IS due to non-compliance or 
post-transplant lymphoproliferative disorders (30). Later, 
the same group designed a prospective trial in which 28 
out of 95 (29%) recipients were successfully weaned off IS 
within a long-term follow-up (31).
 The King’s College group reported also a similar 
experience: out of 18 recipients in which IS withdrawal was 
attempted, 5 (28%) patients were completely weaned off 
from IS drugs, but only 2 were able to remain in an IS-free 
status in the long-term (32).
In 2006, investigators from the Transplant Unit of Tor 
Vergata University described the results of 34 LT recipients 
with recurrent hepatitis C virus (HCV)-related disease in 
whom IS weaning was attempted: among these patients, 
complete IS drugs weaning was successfully achieved in 
8 (23.4%) patients, while the reminders who couldn’t 
complete the IS withdrawal process were returned to the 
initial regimen without any case of graft loss (33). After a 
10-year follow-up, 6 (17.6%) tolerant patients persisted 
in an IS-free status, without any signs of rejection, with 
normal liver function tests (LFTs) and lower incidence of 
IS drug-related side-effects (such as recurrent infection and 
new onset of diabetes mellitus) (10).
More recently, in 2013, the European Consortium of 
transplant tolerance published the results of a prospective 
multicenter trial of IS withdrawal in 102 adult LT recipients 
of cadaveric liver grafts. In this trial, 41 (40%) reached 
the primary endpoint, defined as a stable biochemical and 
histological graft status for at least 1 year after complete IS 
drugs discontinuation (34).
In the last 10 years, 7 major COT trials have been 
reported in LT, which are summarized in Table 1. A total of 
285 tolerant recipients have been investigated, including 
20 (7%) paediatric patients (<18 years) transplanted with 
living donor grafts from consanguineous donors (33-39). 
In most trials, common inclusion criteria were stable graft 
function for at least 1 year and absence of autoimmune 
disease; protocol graft biopsies were performed before 
starting the weaning process to exclude histological signs of 
graft rejection. The mean follow-up from LT to complete 
IS withdrawal was 74 (range: 48–112) months. COT 
was achieved from 22% up to 62.5% of recipients who 
attempted withdrawal of IS drugs. The incidence of acute 
rejection was higher in HCV-positive LT recipients, while it 
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was less frequent in the paediatric population transplanted 
with living-donor grafts (76% vs. 10%, respectively).
These studies demonstrate that tolerant recipients 
present stable graft function after IS weaning in the long-
term follow-up and that complete withdrawal of IS drugs 
could be safely achieved in more than one quarter of 
carefully selected LT recipients without compromising 
patients and grafts survival (9,40).
Predicting factors of tolerance 
Mostly, the aim of the COT trials was to define the 
“predicting factors of tolerance”, which could identify LT 
recipients who could successfully withdraw IS therapy after 
transplantation. So far, the main “clinical predictors of 
tolerance” which have been recognized include: (I) a long 
follow-up period after LT (minimal time of 3 years from 
transplantation to IS weaning); (II) absence of autoimmune 
disease; (III) older LT recipients (>60 years old). 
Moreover, the IS regimen after transplantation seems 
to play also a role in the development of COT. The use of 
CNIs at low-dose during the first post-transplant weeks 
is considered as an independent factor for successful 
IS-weaning due to its interference in the cytokine 
microenvironment, in the pathway of T-cell activation and 
T-receptor down-regulation. However, the immunological 
mechanism of this finding is still not completely clear (41).
In order to identify a priori which patient could be 
potentially tolerant after LT, researchers focused on the 
assessment of the immunological signatures peculiar of 
tolerant and non-tolerant recipients through the identification 
of “biomarkers”. The latter are commonly defined as 
“objective and measurable indicators of physiological 
processes, pathological conditions, or pharmacological 
responses” (42). The “biomarkers of tolerance” were mainly 
explored in peripheral blood using multi-parameter flow 
cytometry, microarrays or real-time PCR gene expression 
profiling, immunophenotypic and genotypic pathway of 
peripheral blood mononuclear cells (PBMCs). 
In 2003, the Pittsburgh group quantified the human 
antigen presenting cells (APC)-dendritic cell subsets in 
6 LT tolerant patients and in 23 non-tolerant recipients. 
Table 1 Operational tolerance trials in liver transplantation recipients
Author, publication 
year
Number of 
patients
HCC 
recipients
Time from LT 
to weaning 
(months)
Complete 
withdrawal IS 
(%)
Follow-up after IS 
withdrawal (months)
Rejection rate 
(%)
Tisone et al., 2006 (33) 34 NA 63.5±20.1 23.4 45.5±5.8 21% acute; 0% 
chronic
Manzia et al., 2013 (10) 28 NA 63.5±20.1 21.4 113±20.02 21% acute; 0% 
chronic
Pons et al., 2008 (35) 12 No 57.5±33.5 38 10–30 58% acute; 
chronic not 
specified
Tryphonopoulos et al., 
2010 (36)
23 No 50.5±3.0 22 87.0±3.0 5% acute; 0% 
chronic
Feng et al., 2012 (37) 20 (paediatric 
LDLT)
No >48 60 32.9 (IQR: 1.0–49.9) 10% acute; 0% 
chronic
De la Garza et al.,  
2013 (38)
24 7 (HCC 
recipients)
112 (IQR: 
72–160)
62.5 (3 HCC 
recipients)
14.0 (IQR: 8.5–22.5) 37.5% acute; 
chronic not 
specified
Benitez et al., 2014 (34) 102 NA 103±47 40.2 48.9 59.8% acute; 
0% chronic
Bohne et al., 2014 (39) 34 NA 86±37 50 12 44.1% acute; 
0% chronic
Values are reported as mean ± standard deviation when available. HCC, hepatocellular carcinoma; IS, immunosuppression; IQR, 
interquartile range; LDLT, living donor liver transplantation; LT, liver transplantation.
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Data showed that the ratio between monocytoid dendritic 
cells, inducing Th1 responses, and plasmacytoid dendritic 
cell, inducing Th2 responses, was significantly lower in 
the tolerant group (43). Later, other studies, analysing the 
immunophenotyping of the PBMCs, found that there was 
an increasing number of CD4+, CD25+ and increased ratio 
γδ1/γδ2 T-cells in tolerant patients (44,45).
Moreover, recently a regulator of CD4+ and CD25+ 
T-reg cells, named FOXP3 gene was found to be strongly 
associated to the tolerance status when detected in 
peripheral blood samples (35).
All these findings suggest that the detection of 
“biomarkers of tolerance” in peripheral blood could help 
identifying patients who can discontinue IS therapy. 
Notably, all the above studies are based on a limited number 
of patients and therefore further clinical trials with larger 
population samples are needed to confirm these results.
HCC and tolerance: state of the art 
So far, there are only few data in the literature on the 
achievement of a stable IS-free status in patients who 
underwent LT for HCC. 
Induction of tolerance to the liver graft after bone 
marrow transplantation was investigated in the last years. 
In 2004, the Ghent-Brussels group described two patients 
who received a right lobe graft from a living donor for 
malignancy (1 HCC and 1 cholangiocarcinoma), after 
CD34+ stem cells harvested from the same donor (46). In 
these series, the main aim was to attempt IS withdrawal 
after LT. The post-operative IS protocol consisted of 
steroids, rapamycin, and anti-thymocyte globulin; IS drugs 
were discontinued after 90 and 28 days from LT, without 
subsequent rejection episodes. In the two cases liver function 
remained stable. The HCC patient died due to tumour 
recurrence after 370 days, while the other was still alive 
after 270 days, but with a suspected cholangiocarcinoma 
relapse. Despite this experience being limited to only two 
cases, this clinical report showed that acceptance of human 
leukocyte antigen (HLA) mismatched living-donor liver 
graft after non-myeloablative conditioning and donor stem 
cell infusion permits to achieve a tolerant status and hence 
could potentially reduce the risk of tumour recurrence by 
improving the rate of immune reconstitution. Later, the 
same group proposed a less drastic conditioning regimen 
(anti-thymocyte globulin and sirolimus combination) 
achieving a state of donor-specific tolerance in other four 
patients. Since these additional case series has only a short 
follow-up reported [5.3±1.8 (range, 3.5–8) months], the 
data do not allow to draw conclusions, yet they suggest that 
further investigations in the field are needed.
The only cases of COT without induction in HCC-LT 
patients were reported by De la Garza et al. in 2013 (38): in 
their trial including a total of 24 patients, 7 (29%) recipients 
underwent LT for HCC. After a mean time of 112 (range, 
72–160) months from IS weaning, 3 (43%) HCC recipients 
presented a tolerant status, while 4 (57%) patients had to 
reassume IS drugs. However, no data on HCC recurrence 
status after IS weaning was reported. 
HCC and tolerance: the Tor Vergata experience
Since 2004, investigators form the Liver Unit of the 
University of Tor Vergata have conducted researches on the 
minimization and discontinuation of IS therapy after LT 
(7,10,11,32,33). In our clinical practice, the post-transplant IS 
protocol is based on a tailored immunosuppressant regimen 
with the aim to (I) minimize IS therapy within 1 year 
after LT (we usually adopt low-dose CNI and steroid-free 
regimen from the first weeks after transplantation); (II) 
attempt IS drugs’ discontinuation after the 3th years from 
LT, in those patients with stable LFTs, who didn’t experience 
previous rejection episodes and/or autoimmune disease. 
During the IS tapering LFTs and clinical examination are 
routinely performed every 4 weeks during drug’s tapering 
and subsequently every 3 months for the first year of the 
weaning process. In case of increases in LFTs, above 2-fold 
the normal levels no further decrease in drug dosages are 
scheduled, and additional LFTs are being performed within 
14 days. Worsening or persistence of biochemical alterations 
is an indication for IS resumption at the same dose before 
the weaning process was started. In case of persistent LFTs 
abnormality, a liver biopsy is usually performed.
In our institution, a total of 113 LT attempted IS 
discontinuation between 2001 and 2016: among these, 37 
(32.7%) patients successfully discontinued IS therapy after LT.
HCC was the primary indication for LT in 17 patients 
[14 M/3 F, median age at LT was 55.5 (range, 43–65) years 
old] who attempted IS withdrawal and their clinical details 
are reported in Table 2. Development of HCC was associated 
with a pre-LT diagnosis of HCV infection in 10 (58.8%) 
cases, hepatitis B virus (HBV) infection in 2 (11.7%), alcohol-
related cirrhosis in 3 (17.6%), co-infection of HBV-HCV 
or HBV-HDV virus in 2 (11.7%). The median time from 
LT to IS withdrawal was 7.6 (range, 2–15) years. At the time 
of IS initiation of weaning, the mean recipient age was 63.2 
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(range, 47–72) years old, 16 (94.1%) patients were receiving 
CNI-based regimens, while 1 (5.9%) were treated with 
m-TORi based therapy. The mean time to wean off IS therapy 
was 6 (range, 2–9) months. After a median follow-up of 25.8 
(range, 14–73) months, 7 (41.1%) LT recipients completely 
discontinued IS drugs and reached a tolerant status, with stable 
LFTs. At the last follow-up, the mean serum level of aspartate 
aminotransferase (AST) was 24 (range, 14–38 ) U/L, alanine 
aminotransferase (ALT) was 23 (range, 17–53) U/L, Total 
bilirubin was 0.7 (range, 0.3–1.4) mg/dL, without clinical and 
biochemical signs of rejection. 
Ten patients (58.9%) were transiently tolerant, defined as 
those LT recipients who presented signs of rejection (LFTs 
above 2-fold normal levels) after IS discontinuation; these 
patients required IS resumption within 5.6 (range, 3–10) 
months from drug cessation, followed by complete recovery 
of graft function and normalization of serum biochemistry. 
No case of non-tolerant patients has been reported [defined 
as LT recipients who presented signs of rejection (LFTs 
above 2-fold normal levels) during IS minimization]. No 
graft and patient loss was observed in the entire follow-
up. Among HCC tolerant group, no evidence of HCC 
recurrence was observed, while 1 (5.88%) transiently 
tolerant patient presented HCC recurrence after 3 years 
from transplantation and died within 4 years. 
Discussion
The role of IS therapy after LT in patients with HCC 
is of paramount importance, in order to avoid acute and 
chronic rejection while protecting the recipients from 
tumour recurrence. The relationship between IS and HCC 
recurrence after LT seems to be evident. The available IS 
regimens inhibit the immune system at many different levels 
simultaneously, weakening both the adaptive and innate 
immune response. This results in a higher susceptibility to 
tumour relapse and de novo malignancy after LT. 
With the currently available IS regimens, the best 
approach to avoid HCC recurrence would be to minimize 
the number and dosage of drugs and to administrate 
tailored IS regimen for HCC recipients as soon as possible 
after LT. Several studies showed that CNIs’ decrease should 
be universally applied at short-term after LT (12,17).
The recent SiLVER study reported that mTORi-based 
IS regimens have a favorable impact on tumour recurrence 
in the first 5 years post LT but seems to not improve the 
recurrence free state beyond 5 years (18). Definitely results 
are awaited from an ongoing prospective randomised open-
labelled clinical trial to better understand mTORi effects on 
tumour recurrence (NCT00355862, available at: http://www.
clinicaltrials.gov). Yet, despite these initial evidences, the best 
IS regimen for patients with HCC is still under debate (47). 
Since a certain degree of immune response is desirable to 
prevent tumour relapse, theoretically, the goal for recipients 
who receive LT for HCC should be a “state of tolerance”. An 
IS-free status could potentially on one hand reduce the risk of 
tumour recurrence, while, on the other hand, have a favorable 
effect on patient outcomes (40). The long-term benefits of IS 
weaning process have been extensively reported: withdrawing 
IS therapy is associated with decreasing drug’s related side-
effects such as cardiovascular diseases, infections, de novo 
tumours, new onset diabetes and dyslipidaemia, as well as 
maintaining a better post-transplant recipients’ compliance 
without compromising graft and patient survival (40). 
A “state of tolerance” can be successfully achieved in about 
25% of carefully selected LT. As mentioned above, results 
from multicentre trials conducted in Europe and the United 
States in adult and paediatric patients have shown that 
COT can be achieved more often than originally estimated. 
Clinical predictor factors, such as stable graft function, 
length of follow-up after LT, IS type and blood levels, close 
matching of HLA type between donor and recipient, absence 
of autoimmune liver diseases, no history of rejection, were 
used as inclusion criteria for patient selection (33-39). 
Long-term results of IS weaning have shown that the 
longer the follow-up after LT the higher the likelihood of 
weaning off IS, consequently most authors prefer to attempt 
weaning 12–36 months after LT (33-34). 
Since some important clinical predictors of COT have 
been identified, in recent years clinicians and scientists have 
focused their attention on determining the immunological 
signature of the tolerant recipients with the aim of 
identifying those patients who could successfully be weaned 
off IS. The development of non-invasive “biomarker 
of tolerance” testing in the setting of LT, mainly based 
on examination of blood samples, currently assumes an 
important role in HCC LT recipients due to the increasing 
likelihood of identifying COT recipients who might be able 
to undergo a reduction of IS or be withdrawn from it. The 
principal role of such biomarkers is to evaluate the immune 
status of recipients, either phenotypic or genotypic, and to 
identify those associated with COT (42). 
In HCC recipients the use of “biomarkers of tolerance” 
might assume a critical role in order to identify which 
patients might potentially early weaned off IS. As it is well 
known, most of HCC recurrence occurs within 2 years 
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after LT, while the IS minimization and/or withdrawal 
is challenging in the early post-transplant period for the 
risk of rejection. Consequently, the use of “biomarkers 
of tolerance” to select patients for drugs withdrawal 
might be crucial. It is conceivable that recipients who 
underwent transplantation for HCC outside the Milan 
criteria might particularly benefit from IS weaning off, 
since the risk of a single episode of acute rejection early 
after LT is easily managed, while tumour relapse has 
limited therapeutic options. 
The Tor Vergata experience is the largest reported so far on 
COT in HCC recipients. Out of 113 LT recipients in whom 
we tried to reach an IS-free status, 17 (15%) received LT for 
HCC. We achieved a tolerant status in 7 (41.1%) cases and 
none presented tumour recurrence after a median follow-
up of more than 2 years. Despite our study population is still 
relatively small, we believe that perhaps all LT recipients who 
had HCC prior to transplant should attempt IS minimization 
schedules and, whenever possible, complete IS withdrawal 
as soon as possible after LT. The selection of patients who 
attempt IS tapering is essential for the good outcome, in 
particular by the identification of non-invasive transcriptional 
and/or serological biomarkers of tolerance (9,40). 
Furthermore, also “oncological” and “non-oncological” 
risk factors have to be considered in the selection process 
of HCC patients who could benefit from IS weaning. 
The presence of risk factors of tumour recurrence such 
as tumour size, number of nodules, histological grading, 
vascular and capsular invasion, pre-transplant alpha-
fetoprotein (AFP) plasma levels, close HLA matching 
between recipient and donor, recipient characteristics (body 
mass index, age), waiting time to transplantation are in 
favour of attempting IS withdrawal.
From a practical point of view, potential candidates who 
could benefit from IS wean should be HCC LT recipients 
with “oncological” and “non-oncological” risk factors for 
tumour recurrence, with normal graft function, without 
autoimmune disease, favourable phenotypic (45) and 
genomic immunological signature (48) and under low dose 
of IS drugs early after transplantation. All these patients 
should undergo liver biopsy before starting IS weaning in 
order to exclude subclinical rejection. IS tapering should 
be started 12 months after LT and should be gradually 
discontinued with the goal of achieving a 50% decrease 
in drug dosage by month 3 and complete withdrawal by 
month 6: meanwhile, patients should be followed every 2–3 
weeks, with liver function tests, for 3 months and monthly 
until month 12 after initiation of the weaning process.
Current prospects and future perspectives 
Several strategies have been investigated to optimize IS 
after LT in order to achieve a IS-free status, including: 
(I) development of target IS regimens (i.e., antibodies or 
fusion proteins direct against molecules involved in T cell 
activation or targeting specific immune cell subsets) (49); 
(II) development of biomarkers to minimize IS (anti-HLA 
antibodies, non-invasive transcriptional or serological 
markers of rejection) (50,51); (III) induction of tolerance 
[e.g., induction of donor-type hematopoietic chimerism 
in living donor liver transplantation (LDLT)] (52); (IV) 
modulation of the liver allograft immunogenicity by the 
use of ex vivo machine perfusion of the liver grafts to 
modulate inflammatory response (53); (V) generation of 
bioengineered liver grafts by using acellular liver scaffolds 
repopulated with patient derived cells (54,55).
All these areas of research are still under evaluation 
and their applicability in the post-transplant setting are 
promising. Moreover, researchers are currently exploring 
the effects of active specific immunotherapy in patients with 
HCC, which could potentially be used also after LT (24).
In conclusion, new clinical trials are in progress to better 
clarify the “immunological jungle” present in the post-
transplantation setting. Despite data are still limited, the 
identification of the immunological printing of COT could 
potentially permit to early select HCC LT recipients who 
can safely withdraw IS therapy in the early post-transplant 
period, in the attempt to reduce the risk of tumour 
recurrence and improve patient and graft outcomes.
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